More news articles

Hemlibra off to a flyer as Roche raises 2019 forecasts

Drug has made almost as much in this quarter as it did in 2018

Gilead drives NASH development with insitro collaboration

Announcement comes days after Novo Nordisk deal

Akcea steals march on Alnylam with NICE approval

Advantage to Tegsedi over Onpattro

Catalent preps for complex therapy boom with $1.2bn Paragon buy

Reflects growing investment in cell and gene therapies

First-in-class hepatitis B/D drug raises cure hope

Those taking the regimen saw virus levels decline

Chi-Med goes for third IPO in Hong Kong

New listing follows first product launch

J&J’s Invokana first SGLT2 to show kidney disease benefits

Could help revival after amputation risk scare

J&J’s targeted bladder cancer treatment gets US approval

Balversa is first FGFR inhibitor

Allergan wins support against dissident shareholders

Shareholders vote on 1 May

Promethera’s liver failure stem cell therapy clears first hurdle

Technique could be alternative to transplant

Novo Nordisk and Gilead join forces in NASH

Will combine semaglutide with Gilead’s cilofexor and firsocostat

Intercept builds its case for Ocaliva in NASH, but safety still an issue

Mixed efficacy and safety results hits NASH frontrunner

No-deal risk recedes, but new Brexit delay adds to uncertainty

Delay means industry must sustain no-deal investment

Galderma launches Rosacea awareness campaign

Campaign comes on the back of Rosacea Awareness Month

Sanofi joins Lilly in insulin price cut, but lawmakers have lost patience

Insulin price nearly tripled between 2002 and 2013

Voice biomarker device could diagnose depression, heart disease

Sonde Health raises $16m in series A round